Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes
Cannabinoid type-1 receptor (CB1R) expression is increased in the posterior hippocampus of aged Down syndrome (DS) subjects and Ts65Dn mice. Long-term rimonabant treatment enhances memory in middle-aged Ts65Dn mice. CB1R inhibition shifts neuroinflammatory features in Ts65Dn mice. CB1R inhibition does not halt noradrenergic/cholinergic neurodegeneration in Ts65Dn. CB1R inhibition presents potential for memory improvement in DS-related deficits.
Authors
- Anna Vázquez‐Oliver (ORCID: https://orcid.org/0000-0002-9842-7656)
- Laura Molina‐Porcel (ORCID: https://orcid.org/0000-0003-4068-8578)
- Nieves Pizarro (ORCID: https://orcid.org/0000-0003-2671-7184)
- Rafaël Maldonado (ORCID: https://orcid.org/0000-0002-4359-8773)
- Andrés Ozaita (ORCID: https://orcid.org/0000-0002-2239-7403)
- Rafael de la Torre (ORCID: https://orcid.org/0000-0002-6765-1866)
- Silvia Pérez‐García
- Diana Galarraga‐Shinin
- Rafael Romero‐Pérez
Institutions
- Universitat Pompeu Fabra (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Del Mar (ES)
- Fundació Clínic per a la Recerca Biomèdica (ES)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1002/alz.70874
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministerio de Ciencia, Innovación y Universidades
- Fondation Jérôme Lejeune
- Generalitat de Catalunya
- Institució Catalana de Recerca i Estudis Avançats
- Ministerio de Sanidad, Servicios Sociales e Igualdad
- Agencia Estatal de Investigación